| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98374f168c43d1b57d81c37017bfcef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2cd0454dd1dc095d90cd25a293cd1fa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J19-0046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-00 |
| filingDate |
2013-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9a696d7a26299e3b24842f74f290f99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_554ddbbd2c17d5911273b45873eab2cc |
| publicationDate |
2013-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013188600-A1 |
| titleOfInvention |
Copy number aberration driven endocrine response gene signature |
| abstract |
Disclosed are methods of predicting the likelihood of long-term survival without recurrence of breast cancer for a subject having estrogen receptor-positive (ER+) breast cancer treated with adjuvant endocrine monotherapy. In various embodiments, these methods comprise performing a gene expression profile of a breast tissue sample of substantially all of the genes of the "CADER set" described herein; calculating a risk score using a regression model; and applying a double median cutoff classification to assign the subject to a sensitive, indeterminate or resistant group, wherein assignment to a sensitive group predicts longer relapse-free survival compared to the median relapse-free survival of ER+ breast cancer patients treated with adjuvant endocrine monotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108090328-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113506309-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108090328-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017096457-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10607717-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016368696-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11574704-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109072481-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10851427-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019051266-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11505832-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11566292-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2541405-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109072481-B |
| priorityDate |
2012-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |